NCT04642157 Online Referral and Intervention to Prevent Adolescent and Young Adult Suicide
| NCT ID | NCT04642157 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Lille |
| Condition | Suicide |
| Study Type | INTERVENTIONAL |
| Enrollment | 396 participants |
| Start Date | 2022-10-13 |
| Primary Completion | 2026-07-13 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 396 participants in total. It began in 2022-10-13 with a primary completion date of 2026-07-13.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
ORIAS is a randomized controlled trial designed to study the efficacy of the ELIOS system in reducing suicidality in the AYA, reinforcing their motivation to seek help and making them access to care. As ELIOS would be the first suicide prevention system worldwide entirely tailored to the AYA contemporaneous modes of interaction on social media, ORIAS was designed to address the challenge of deciding whether this innovation is worth adding to the current national and international prevention arsenal. While randomized control trials are crucially lacking in the field of suicide prevention, especially on the Internet, the high-level evidence that ORIAS is expected to bring could have a decisive influence on how the French prevention strategies will seize the social media.
Eligibility Criteria
Inclusion Criteria: * To spontaneously contact the ELIOS online system * To have been experiencing suicidal ideations in the week prior the contact * To live in France and speak French * To provide informed consent For ethical reasons, we decided not to include minors, due to impossibility of getting the parental authorizations without compromising the facilitation role of the system. However, most recent expert consensus consider that adolescence extends to 25 years old. Exclusion Criteria: * To contact the ELIOS online system for a relative or an acquaintance
Contact & Investigator
Charles-Edouard Notredame, MD
PRINCIPAL INVESTIGATOR
CHU Lille
Frequently Asked Questions
Who can join the NCT04642157 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 25 Years, studying Suicide. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04642157 currently recruiting?
Yes, NCT04642157 is actively recruiting participants. Contact the research team at charles-edouard.notredame@chru-lille.fr for enrollment information.
Where is the NCT04642157 trial being conducted?
This trial is being conducted at Lille, France.
Who is sponsoring the NCT04642157 clinical trial?
NCT04642157 is sponsored by University Hospital, Lille. The principal investigator is Charles-Edouard Notredame, MD at CHU Lille. The trial plans to enroll 396 participants.